《2025年世界卫生组织全球疫苗市场报告》

Global Vaccine MarketReport2025Insights across four topics Vaccine-specificsupply dynamicsand supply securityRegions have diverse Volumeand financial value2024 volume of 7.2 billion doses and Manufacturingand supplyMarket remains highly Procurementand pricingProcurement and pricing concentrated patterns remain stable financial value of US$66.5 billion reliance of vaccine supply▪Most of the top 20 markets havea high account for78% of vaccine dosesandthetop 10 by financial valueaccount for84% of the total▪In 2024,114 additional manufacturersaccounted for the remaining countries (MICs) and UNICEF pooledprocurement accounted for largeshare of global volumes,representing ~44% and 37%,respectively▪Vaccine prices within individualmarkets tend to be tieredacross doses-7% higher than in 2023▪Total financial value of US$6.5 billion-13% lower than in 2023, with volumes ofCOVID-19 vaccines falling by 40%▪HPV and shingles maintained a highcompound annual growth rate(CAGR)in volume (14% and 11% respectively)between 2019 and 2024▪COVID-19, HPV and PCVwere thehighest in financial value▪A total market value growth rate of>9% between 2019 and 2024 hasoutpaced the volume rate of 3.5%,driven by a higher-priced portfolio mixattributed to RSV, COVID-19,MenB number of manufacturers per vaccine andhigh market-share concentration in twomanufacturers▪Countries in the WHO African andEastern Mediterranean regions procure global volumes▪About two thirds of doses wereprocured from manufacturers almost entirely(>95%)frommanufacturers outside of theirrespective regions▪The WHO South-East Asia and WesternPacific regions look highly self-reliant:▪ countries based on their income groupHPV, PCV and Rota markets exhibitwide price rangesdue to the several affiliated with the Developing CountryVaccine Manufacturers Network(DCVMN) in 2024 different products in the market ▪89% of vaccine volumes in the South-East Asia region are supplied though manufacturers in the same region▪74% of vaccine volumes in the WesternPacific region are supplied thoughmanufacturers in the same region Insights:GVMR2025Volume and financial value Global Vaccine MarketReport2025 Total marketvolumes of 7.2 billiondoses, 7% higherthan in 2023 doses from 2023, primarily due tohighuse of oral polio vaccine (OPV) in 2024•OPV, seasonal influenza (IIV) and COVID-19together contribute~50% ofvolumein 2024 Total financial value ofUS$66 billion was 13%lower than in 2023 financial value▪COVID-19 accounted for 16% of total valueat US$11 billion▪HPV and shingles have grown the mostin financial value since 2019*▪All top 10 vaccines hadpositive growthrates from 2019 to 2024,mainly linked to expandingvolumes▪A total financial value growth rate of >9% between 2019 and 2024 has outpaced thevolume rate of 3.5%,driven by a higher-pricedportfolio mix attributed to RSV, COVID-19,MenB*Excluding RSV and COVID-19 that were not available in 2019 Volume and financial value Most vaccines did not experience notable variation,with the exceptionofCOVID-19 and OPV Percentage changein the top 20 vaccine markets by volumeor value in 2024, showing change between 2023 and 2024 COVID-19Value decrease driven by volume decrease:▪64% in HICs ▪40% in UMICs▪1% in LMICs/LICs Switches to PCV in US, EUR and WPR HICs ▪2-dose schedule (eradication)▪50% China increase OPV▪Larger presentations nOPVdrives value increase with price~30% higher thanbOPV Little change involumes andfinancial valuecompared to 2023except for theCOVID-19 decline▪More than half of IIV volumes are in EUR and AMR▪AMR and the US account for ~50% of value for several vaccines (COVID-19, IIV, PCV, M-containing, Rota, Shingles, RSV andMenB)▪In 2024 China accounted for half the financial value of the HPV market, all fromthe private sectorSeasonal influenza vaccine was renamed in 2024 to separatedifferent types of influenza vaccines. Inactivated influenza vaccine = Measles, MR, MMR, MMRV Insights:GVMR2025Manufacturing and supply More than 78% oftotal volume wasconcentrated in thetop 10 manufacturersin 2024 ▪Pfizer’s share of volume decreased from 11% in 2023 to 6% in 2024.▪Moderna, the remaining vaccine producer with only one product (COVID-19) in theportfolio , is no longer top 10.SII is the dominant manufacturer by volume, accounting for 2-fold greater volume than thenext largest manufacturer▪The top 5 manufacturersaffiliated with DCVMN provided 55% of all volume More than 84% of totalfinancial value wasconcentrated in thetop 10 manufacturersin 2024 in 2023;▪declining COVID-19 vaccine use caused Merck to swap positionswith Pfizer;▪Moderna’s share about half of 2023 Manufacturers affiliated with IFPMA were responsible for 80% of totalfinancial value, about same as in 2023 ▪Global vaccine marketvalue split between afew large manufacturerswith broad portfolioscovering multipleantigens and multipletechnology types value and volume perspectives▪Below the 2 billion US$ line(mainly) manufacturersHQ’d